belimumab
gsk
['lupus']
 abs 1636 urowitz, et al.
toronto lupus cohort n=179 they used the 1* efficacy renal response from bliss-ln (mperr) at 2 yrs as the exposure of interest outcome: long term renal survival after ln dx #acr22
@bu_bmc_rheum | @rheum_covid @spartan_updates @official_asas | @UWRheum @UWEpidemiology 2020 | @OHSUIMres 2017 | @UTMBhealth 2014 | @UTAustin 2010